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Abstract: 
Malaria is an important tropical infection which urgently requires intervention of an effective vaccine. Antigenic variations of the parasite and 
allelic diversity of the host are main problems in the development of an effective malaria vaccine. Cytotoxic T lymphocytes (CTL) directed 
against Plasmodium falciparum-derived antigens are shown to play an important role for the protection against malaria. The merozoite surface 
protein 1 (MSP1) is expressed in all the four life-cycle stages of Plasmodium falciparum and did not find any sequence similarity to human and 
mouse reference proteins.  MSP1 is a known target of the immune response and a single CTL epitope binding to the HLA-A*0201 is available for 
merozoite form. Here, we report the results from the computational characterization of MSP1, precursor (1720 residue) and screening of highest 
scoring potential CTL epitopes for 1712 overlapping peptides binding to thirty four HLA class-I alleles and twelve HLA class-I supertypes (5 
HLA-A and 7 HLA-B) using bioinformatics tools. Supertypes are the clustered groups of HLA class-I molecules, representing a sets of molecules 
that share largely overlapping peptide binding specificity. The prediction results for MSP1 as adhesin and adhesin-like in terms of probability is 
1.0. Results also show that MSP1 has orthologs to other related species as well as having non allergenicity and single transmembrane properties 
demonstrating its suitability as a vaccine candidate. The predicted peptides are expected to be useful in the design of multi-epitope vaccines 
without compromising the human population coverage.  
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Background: 
Malaria infects 500 million people and kills an estimated 2.7 million 
annually, representing one of the most significant diseases in the world 
[1]. It is caused by four species of the genus Plasmodium, in humans, 
of which Plasmodium falciparum is the most virulent that infect and 
destroy red blood cells [2].  Plasmodium falciparum strains have 
evolved resistance against known anti-malarial drugs [3] and yet, no 
effective vaccine is available against malaria for mass production. 
Malarial vaccine development is probably hampered by the several 
factors such as multiple stages of the life-cycle, multiple antigens per 
stage, multiple epitopes per antigen, multiple arms of the immune 
system, multiple immune responses in different hosts and multiple 
strains of the parasite [4].  
 
Malarial immunity is a stage specific and the previous strategies are 
being used to develop a vaccine against each stage–sporozoite, asexual 
blood stage and sexual stages. A vaccine against a single stage in the 
life-cycle need to be 100% effective, because parasite that progress to 
the next stage may express a new set of antigens, which may be 
unaffected by the vaccine induced immune responses [5]. Although, a 
good number of candidates for such vaccines exist [6], however, it is 
an accepted view that an effective malaria vaccine need to target all 
the life-cycle stages of the parasite as well as allelic diversity of the 
human host.  
 
The recent approaches such as genome sequence analysis, microarray, 
proteomics and computational vaccinology can be effectively applied 
for vaccine development of several diseases including malaria [7]. In a 
large-scale, high-accuracy mass spectrometric proteome analysis, 152 
proteins were found common to the four stages of Plasmodium 
falciparum life-cycles [8]. One of these common proteins, merozoite 
surface protien 1 (MSP1), normally found in a number of Plasmodium 
species is synthesized as a high-molecular-weight precursor (190 kDa) 
and then processed into several fragments. At the time of red blood 
cell invasion by the merozoite, only the 19-kDa C-terminal fragment 
remains on the cell surface. The full-length MSP1 as well as 
processing fragments expressed in Escherichia coli have been 
evaluated as vaccines [9]. Antibodies against MSP1 also inhibit 
merozoite entry into red blood cells and immunization with MSP1 
protects monkeys from infections [10]. Therefore, MSP1 may have 
importance as a protective immunogen in novel vaccine formulation 
[11].  
 
Although several CD8
+ cytotoxic T lymphocyte
 (CTL) epitopes have 
been identified from Plasmodium falciparum sporozoite-derived 
antigens, recently a single epitope has also been described for the 
merozoite form [12]. However, the full range of CTL epitopes present 
in MSP1 still remains unknown. The precise characterization of the 
immunogenic sequences from MSP1, involved in the cytotoxic 
immune response, i.e. the MHC class-I epitopes, is critical for in vitro 
monitoring of the therapeutically induced anti- Plasmodium 
falciparum CTL responses in patients for peptide-based vaccine 
development. In this article, we report the characterization of MSP1, 
precursor antigen as a suitable vaccine candidate followed by 
identification of the HLA class-I binding epitope using bioinformatics 
tools. The predicted CTL epitopes may be evaluated as potential 
components of malaria vaccine formulation that circumvent the 
problems associated with the host genetic restriction and antigenic 
variability.  
 
Methodology:  
Target protein sequence retrival:  
A comprehensive set of the protein complements has been isolated 
from sporozoites, merozoites, trophozoites and gametocytes of the 
Plasmodium  falciparum 3D7. About 46% of all the gene products 
(2,415 parasite proteins) were detected in all the four stages of 
Plasmodium falciparum life-cycle and only 6% (152 proteins) were 
common to four stages [13]. One of these common proteins, MSP1 
was targated for the characterarization as a vaccine candidate and their 
immunogenic regions analysis. The amino acid sequence of the MSP1 
(Orfid: PFI1475w; chromosome: 9) was retrieved from the PlasmoDB 
database [14].  
 
Vaccine candidate characterization tool:  
The vaccine candidate characterization of MSP1 was done using 
various computational tools such as Vaxijen, MAPP, SPAAN, Bioinformation   open access 
www.bioinformation.net    Hypothesis
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TargetP, SignalP and TMHMM. The conserved domain and similarity 
to the human and mouse reference proteins of MSP1 were searched 
using NCBI’s conserved domain database [15]. The orthologs of the 
MSP1 related to the other Plasmodium species were also searched 
using OrthoMCL database [16].  
 
Immunogenic region analysis tool:  
Here, we used Immune Epitope Database (IEDB) analysis resources 
such as ARB, SMM and ANN available at http://tools-int-
01.liai.org/analyze/html/mhc_processing.html to predict CTL epitopes 
for thirty four HLA alleles. The software tool combines predictions of 
proteasomal cleavage processing, TAP transport and MHC binding to 
produce an overall score for each peptide as well as intrinsic potential 
value for CTL epitope. The default setting parameters were used for 
the immunoproteasome cleavage and TAP transporter predictions. The 
results of computational analysis included peptide sequences, their 
start positions and corresponding IC50 values. In order to, predict 
supertype CTL epitopes in MSP1, a web based software tool 
(NetCTL-2.1) available at http://www.cbs.dtu.dk/services/NetCTL 
was used. The NetCTL-1.2 server demonstrated a better predictive 
performance than other available web servers like EpiJen, MAPPP, 
MHC-pathway and WAPP on all performance measures [17]. In order 
to, classify 1712 overlapping peptides into binders and non-binders to 
twelve HLA class I supertypes (5 HLA-A and 7 HLA-B), the 
transformed binding affinity value of ≥ 0.426 (equivalent to affinity ≤ 
500 nM) was used. To get, an average optimal predictive performance, 
the default weight on C terminal cleavage and TAP transport 
efficiency was used as 0.1 and 0.05 respectively. The peptides with a 
combined processing score value ≥ default threshold value (0.75) were 
predicted as potential supertype CTL epitopes.  
 
Discussion: 
The characterization  of  Plasmodium falciparum proteome by 
multidimensional protein identification technology showed that 46% 
of all gene products (2,415 parasite proteins) were detected in all the 
four stages of the life-cycle. Almost half (49%) of the sporozoite 
proteins were unique to this stage and shared on an average 25% of its 
protein to other stages. On the other hand, trophozoites, merozoites 
and gametocytes have 20-33% unique proteins and shared their 39-
56% proteins. Consequently, only 152 proteins (6%) were common to 
all four stages of the parasite life-cycle (Figure 1). These common 
proteins were mostly housekeeping proteins such as ribosomal 
proteins, transcription factors, histones and cytoskeletal proteins [13]. 
One of these common proteins, MSP1 has the potential to become a 
suitable vaccine candidate which also contained domains that indicate 
a role in cell-cell interactions [18].  
 
The characterization of the targeted MSP1 antigen as a vaccine 
candidate was performed using a number of computational tools 
available in the public domain. The MSP1 was predicted as a subunit 
vaccine candidate using Vaxijen server with a score of 0.57. The 
prediction of MSP1 as adhesin and adhesin-like was done using 
MAAP and SPANN servers based on their prediction probabilities of 
1.00 and 0.65, respectively (Table 1 in supplementary material).   
The prediction of localization of MSP1 in a secretory pathway with 
signal peptide probability of 0.94 and 1.0 was done using TargetP1.1 
and SignalP 3.0 servers. MSP1 having single transmembrane spanning 
region were predicted using TMHMM server. The exhaustive search 
for orthologs and conserved domains based on homology prediction 
was performed using OrthoMCL and NCBI's CDD databases. The 
MSP1 has two orthologs namely Plasmodium vivax-Pv099980 and 
Plasmodium yoelii-PY05748. The similarity to the human and mouse 
reference proteins were also searched using the BlastP server (Table 1 
in supplementary material). MSP1 did not find any sequence 
similarity to human and mouse reference database. A vaccine 
candidate with similar sequences to the host i.e. human or mouse is 
likely to cause autoimmunity in the host. Non allergenicity of the 
MSP1 protein was also predicted using Algpred and Allermatch tools.  
Here, MSP1 demonstrated all the desirable properties of a suitable 
vaccine candidate (Table 1 in supplementary material).  
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Figure 1: Clusters of proteins expressed in different stages of the P.falciparum 3D7 life-cycle (Spz- Sporozoites, Mrz-Merozoites, Tpz-  
Trophozoites and Gmt-Gametocytes) Bioinformation   open access 
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Figure 2: A comparative evaluation of CTL epitope processing prediction algorithms available at IEDB (ANN-Artificial Neural Network,    
ARB-Average Relative Binding and SMM-Stabilized Matrix Method) for thirty four HLA class-I alleles 
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Figure 3: The predicted highest scoring CTL epitopes in MSP1, precursor binding to twelve HLA-A and B supertypes using NetCTL2.1 
algorithm. Peptides are shown with their start position in the native protein. 
 
A total seventeen CD8+ epitopes have been identified from P. 
falciparum sporozoite-derived antigens and available at IEDB as on 
15
th March, 2009. The latest one, a single CTL epitope binding to the 
HLA-A*0201 for merozoite form is additional [12]. However, the full 
range of CTL epitopes binding to other HLA class-I molecules present 
in MSP1 still remains unknown. Therefore, the binding information 
regarding thirty four HLA class-I epitopes was predicted using IEDB 
analysis algorithms like ARB, SMM and ANN, whereas, supertype 
CTL epitopes were predicted using NetCTL2.1 algorithm. The best 
performing method for the individual HLA class-I molecules was used 
for epitope mapping of MSP1 (Figure 2). According to the analysis, 
peptides with the best predicted binding affinities for each HLA class-I 
molecules are presented in (Table 2 in supplementary material). The 
predicted output is given in units of IC50 nM. A lower value of peptide Bioinformation   open access 
www.bioinformation.net    Hypothesis
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IC50  indicates higher affinity towards MHC molecule. As a rough 
guideline, peptides with IC50 values <50 nM, <500 nM and <5000 nM 
are considered having high affinity, intermediate affinity and low 
affinity towards MHC molecule respectively. Among all HLA alleles 
and peptides, the promiscuous peptide FLSSGLHHL (position: 1195-
1204) binds with the two HLA alleles A*0202 and A*0203, peptide 
KIFSARYTY (position: 532-541) binds with four alleles A*0301, 
A*1101, A*3002 and A*3101 and peptide VPYPNGIVY (position: 
419-427) binds with two allele B*3501 and B*5101 [19]. In order to, 
reach for a consensus prediction by other alternative software tools, 
the predicted highest scoring CTL epitopes by most accurate method 
were also ranked by two other alternative methods [20] (Table 1 in 
supplementary material).. Most of the highest scoring CTL epitopes, 
predicted by one method were also ranked within five by other 
alternative tools. In addition to, HLA class-I allelic CTL epitope 
prediction, MSP1 was also searched for putative HLA-A and B 
supertype CTL epitopes. The highest scoring predicted supertype CTL 
epitopes are shown in the Figure 3. In this study, none of the highest 
scoring predicted CTL epitopes shared sequence identity to human 
proteins, therefore, they could be included in malaria vaccine design 
except the peptide sequence IFFLCSFLFFI (position:4-15), which 
corresponds to the signal peptide.  
 
Conclusion: 
Identification of epitopes capable of binding to multiple HLA alleles 
and supertypes shall significantly rationalize the development of 
epitope-based vaccines. The present study can be considered as a good 
example of application of advanced bioinformatics techniques in CTL 
epitope prediction. The promiscuous and supertype peptide binders 
allow reducing the time and minimizing the total number of predicted 
epitopes required for wet lab tests without compromising the 
population coverage. As per our knowledge, the highest scoring 
predicted epitopes using IEDB analysis resource and NetCTL are 
reported first time and could eventually be proposed as a component of 
a peptide-based anti-malaria vaccine. However, this study has some 
limitations, as it reports only predicted results and further validation is 
required through in vitro synthesis of the determined peptides. 
Besides, in vivo experimental study has to be done, in order to, finally 
test the efficacy of malaria vaccine.  
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Supplementary Material 
Table 1: Computational characterization of MSP1, precursor as a suitable vaccine candidate 
Prediction Characteristics  Status 
Vaxijen prediction as a antigen  Yes (0.5706) 
MAAP prediction as a adhesin and adhesin-like    Yes (1.00) 
SPAAN prediction as a adhesin and adhesin-like   Yes (0.615) 
Localization Secretory  Pathway  TargetP prediction for subcellular localization 
Signal peptide probability  0.94 
Number of TM Helices  1  TMHMM prediction for transmembrane regions 
Topology outside1696-1718inside 
Signal peptide probability  1.00  SignalP prediction for signal peptide 
Is signal peptide  Yes 
P.Vivax Yes  (Pv099980)  Orthologs prediction to other Plasmodium species  
P. Yoelii Yes  (PY05748) 
Using Algpred  Non Allergen  Allergenicity prediction 
Using Allermatch 
Similarity to human and mouse proteins using BlastP 
Conserved Domain Database hits using BlastP 
Non Allergen 
No 
pfam07462, MSP1_C,  
CD Length: 574   
 
Table 2: The predicted highest scoring CTL epitopes in MSP1, precursor using IEDB algorithms (ARB, SMM and ANN) 
ARB SMM ANN  Human  
MHC  
Class-I 
allele 
 Peptide 
sequence 
Start 
position  MHC 
affinity 
(IC50) 
Total 
processing 
Score (Rank) 
MHC 
affinity 
(IC50) 
Total processing 
Score  
(Rank) 
MHC 
affinity 
(IC50) 
Total 
processing 
Score (Rank) 
A*0101 FTDPLELEY  384  4.5  1.94(1)  15.9  1.40(1)  5.4  1.86(1) 
A*0201 FLCSFLFFI  6  0.0  2.60(1)  1.0  1.17(1)  2.5  0.76(6) 
A*0202 FLSSGLHHL  1195  0.8  1.98(3)  1.6  1.66(1)  2.7  2.72(1) 
A*0203  FLSSGLHHL  1195   0.7  2.00(1)   3.8  1.28(1)  1.39  3.0(1) 
A*0206  MQIKKLTLL 1080 10.3 0.82(4)  7.5  0.96(4)  5.2  1.12(1) 
A*0301 KIFSARYTY  532  1.0  1.27(1)  304.2  0.43(1)  69.3  1.07(1) 
A*1101 KIFSARYTY  532  130.6  0.80(5)  100.7  0.91(1)  1207.4  -0.17(14) 
A*2301 FFLCSFLFF  5  3.3  2..08(2)  90.3  0.64(1)  33.1  1.08(1) 
A*2402  IFFLCSFLF  4 18.9 1.33(1)  268.0  0.18(1)  na  na 
A*2403  VYLKKLDEF 798 0.6 2.6(1)  1.7  2.13(1)  3.3  1.85(1) 
A*2601 LLILMLILY  1709  7.2  1.85(1)  205.2  0.4(1)  23.4  3.4(1) 
A*2902 YYEKVLAKY  1447  7.6  1.86(4)  34.4  1.20(5)  20.7  1.42(1) 
A*3001 KLKKALSYL  563  9.6  0.88(2)  28.8  0.40(5)  4.9  1.17(1) 
A*3002 KIFSARYTY  532  2.2  2.57(3)  35.3  1.37(1)  12.2  1.82(1) 
A*3101 KIFSARYTY  532  158.6  0.71(4)  251.9  0.51(1)  89.4  0.96(1) 
A*3301 DYCQIPFNL  214  1.5  1.80(3)  64.3  0.16(1)  16122 -2.24(116) 
A*6801 YTYNVEKQR  538  2.76  0.2(1)  1.23  6.6(1)  na  na 
A*6802 ETVGHTTTV  753  0.9  1.29(2)  9.9  0.23(1)  na  na 
A*6901  EMIYYLHKL  883 11.9 0.86(3)  51.8  0.22(1)  na  na 
B*0702  SPSSRSNTL  109 25.4 0.27(1) 31.7  0.17(1)  3.4 1.15(1) 
B*0801 RLKKRKYFL  1380  2.1  1.70(1)  1.8  1.76(1)  3.6  1.46(1) 
B*1501 YLKPLAGVY  1347  75.2  0.93(15)  32.0  1.30(1)  42.8  1.17(3) 
B*1503 FKHISSNEY  1398  0.5  2.89(1)  0.7  2.78(1)  na  na 
B*1517 LSFDLYNKY  1053  156.9  0.56(32)  3.5  2.20(1)  na  na 
B*1801  NEYIIEDSF  1404 28.1 1.10(4)  24.8  1.16(1)  8.2  1.64(3) 
B*2705  SRLKKRKYF 1379 94.3 0.62(1)  279.9  0.14(1) 135.5  0.46(1) 
B*3501 VPYPNGIVY  419  93.5  0.81(10)  64.2  0.98(1)  23.2  1.42(1) 
B*4001  KEIAKTIKF  370 86.8 0.76(2)  539.4  -0.04(2)  34.6  1.15(1) 
B*4002  KDFNHYYTL  583 27.3 0.63(5)  19.0  0.79(1)  11.6  1.01(1) 
B*4402 KEIAKTIKF  370  532.7  -0.03(3)  na  na  60.4  0.9(1) 
B*4403  NELLYKLNF  190 57.1 0.73(1)  33.0  0.97(1)  83.6  0.56(4) 
B*4501 SEKDFNHYY  581  635.5  -0.28(5)  595.8 -0.25(2)  108.0 0.49(1) 
B*5101 VPYPNGIVY  419  687.4  -0.05(6) 2578.6  -0.63(2)  742.1  -0.09(1) 
B*5301 NPHNVLQNF  1101  5.6  1.68(1)    83.5  0.51(2)  39.6  0.83(1) 
B*5401 
B*5701 
B*5801 
IPFNLKIRA 
KALSYLEDY 
ISTTEMEKF 
218 
566 
994 
15.7 
107.0 
139.3 
-0.20(3) 
0.53(1) 
0.44(5) 
14.2 
 361.4 
154.2 
-0.15(1) 
0.01(1) 
0.39(1) 
25.2 
228.8 
127.5 
-0.16(2) 
0.21(1) 
0.47(2) 
na - not available for prediction  